Sunday, 27 December 2009

Calcium Fresenius




Calcium Fresenius may be available in the countries listed below.


Ingredient matches for Calcium Fresenius



Calcium

Calcium mixture of several salts (a derivative of Calcium) is reported as an ingredient of Calcium Fresenius in the following countries:


  • Austria

International Drug Name Search

Thursday, 17 December 2009

Paroxetine Apotex




Paroxetine Apotex may be available in the countries listed below.


Ingredient matches for Paroxetine Apotex



Paroxetine

Paroxetine hydrochloride (a derivative of Paroxetine) is reported as an ingredient of Paroxetine Apotex in the following countries:


  • Belgium

International Drug Name Search

Friday, 11 December 2009

oxacillin


Generic Name: oxacillin (ox a SIL in)

Brand names: Bactocill, Oxacillin Sodium ADD-Vantage


What is oxacillin?

Oxacillin is an antibiotic in the penicillin group of drugs. It fights bacteria in your body.


Oxacillin is used to treat many different types of infections caused by bacteria, such as a staphylococcal (also called "staph") infection.


Oxacillin may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about oxacillin?


Do not use this medication if you are allergic to oxacillin or to any other penicillin antibiotic, such as amoxicillin (Amoxil), ampicillin (Omnipen, Principen), carbenicillin (Geocillin), dicloxacillin (Dycill, Dynapen), penicillin (Beepen-VK, Ledercillin VK, Pen-V, Pen-Vee K, Pfizerpen, V-Cillin K, Veetids), and others.

Before using oxacillin, tell your doctor if you are allergic to cephalosporins such as Ceclor, Ceftin, Duricef, Keflex, and others, or if you have asthma, liver disease, kidney disease, or a history of any type of allergy.


Oxacillin can make birth control pills less effective, which may result in pregnancy. Before taking oxacillin, tell your doctor if you use birth control pills. Take this medication for the entire length of time prescribed by your doctor. Your symptoms may get better before the infection is completely treated. Oxacillin will not treat a viral infection such as the common cold or flu. Do not share this medication with another person, even if they have the same symptoms you have.

Antibiotic medicines can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or has blood in it, call your doctor. Do not use any medicine to stop the diarrhea unless your doctor has told you to.


What should I discuss with my healthcare provider before taking oxacillin?


Do not use this medication if you are allergic to oxacillin or to any other penicillin antibiotic, such as:

  • amoxicillin (Amoxil, Amoxicot, Biomox, Dispermox, Trimox);




  • ampicillin (Omnipen, Principen);




  • carbenicillin (Geocillin);




  • dicloxacillin (Dycill, Dynapen);




  • penicillin (Beepen-VK, Ledercillin VK, Pen-V, Pen-Vee K, Pfizerpen, V-Cillin K, Veetids, and others).



Before using oxacillin, tell your doctor if you are allergic to any drugs (especially cephalosporins such as Ceclor, Ceftin, Duricef, Keflex, and others), or if you have:



  • asthma;




  • liver disease;




  • kidney disease;




  • a bleeding or blood clotting disorder;




  • a history of diarrhea caused by taking antibiotics; or




  • a history of any type of allergy.



If you have any of these conditions, you may need a dose adjustment or special tests to safely take oxacillin.


FDA pregnancy category B. This medication is not expected to be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. Oxacillin can make birth control pills less effective, which may result in pregnancy. Before taking oxacillin, tell your doctor if you use birth control pills. Oxacillin can pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I take oxacillin?


Take this medication exactly as it was prescribed for you. Do not take the medication in larger amounts, or take it for longer than recommended by your doctor. Follow the directions on your prescription label.


Take the medicine with a full glass of water. Oxacillin should be taken on an empty stomach, at least 1 hour before or 2 hours after eating a meal.

To be sure this medication is helping your condition, your blood will need to be tested on a regular basis. Your kidney or liver function may also need to be tested. Do not miss any scheduled visits to your doctor.


Take this medication for the entire length of time prescribed by your doctor. Your symptoms may get better before the infection is completely treated. Oxacillin will not treat a viral infection such as the common cold or flu. Do not share oxacillin with another person, even if they have the same symptoms you have.

This medication can cause you to have unusual results with certain medical tests. Tell any doctor who treats you that you are using oxacillin.


Store oxacillin at room temperature away from moisture, heat, and light.

See also: Oxacillin dosage (in more detail)

What happens if I miss a dose?


Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the medicine at your next regularly scheduled time. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention if you think you have used too much of this medicine.

Overdose symptoms may include confusion, behavior changes, a severe skin rash, urinating less than usual, or seizure (black-out or convulsions).


What should I avoid while taking oxacillin?


Antibiotic medicines can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or has blood in it, call your doctor. Do not use any medicine to stop the diarrhea unless your doctor has told you to.


Oxacillin side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have any of these serious side effects:

  • fever, sore throat, and headache with a severe blistering, peeling, and red skin rash;




  • diarrhea that is watery or bloody;




  • fever, chills, body aches, flu symptoms;




  • easy bruising or bleeding, unusual weakness;




  • urinating less than usual or not at all;




  • severe skin rash, itching, or peeling;




  • agitation, confusion, unusual thoughts or behavior; or




  • seizure (black-out or convulsions).



Less serious side effects may include:



  • nausea, vomiting, stomach pain;




  • vaginal itching or discharge;




  • headache;




  • swollen, black, or "hairy" tongue; or




  • thrush (white patches or inside your mouth or throat).



This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.


Oxacillin Dosing Information


Usual Adult Dose for Endocarditis:

Native valve endocarditis due to staphylococci:
Oxacillin 2 g IV every 4 hours or 3 g IV every 6 hours (total 12 g/day) with or without gentamicin 3 mg/kg/day in 2 or 3 divided doses.

Duration: Oxacillin, 6 weeks; gentamicin 3 to 5 days


Prosthetic valve endocarditis due to staphylococci:
Oxacillin 2 g IV every 4 hours or 3 g IV every 6 hours (total 12 g/day) plus rifampin 300 mg orally every 8 hours, with or without gentamicin 3 mg/kg/day in 2 or 3 divided doses.

Duration: Oxacillin and rifampin, 6 weeks or more; gentamicin 2 weeks

Refer to current published guidelines for detailed recommendations.

Usual Adult Dose for Joint Infection:

2 g IV or IM every 4 to 6 hours for 3 to 4 weeks, depending on the nature and severity of the infection. Longer therapy, for 6 weeks or more, may be required for prosthetic joint infections. A third-generation cephalosporin, ciprofloxacin, and/or rifampin should be added, depending on the results of the Gram stain.

Usual Adult Dose for Meningitis:

2 g IV or IM every 4 hours for 14 days, depending on the nature and severity of the infection.

Usual Adult Dose for Osteomyelitis:

2 g IV or IM every 4 hours for 4 to 6 weeks, depending on the nature and severity of the infection. Chronic osteomyelitis may require additional oral antibiotic therapy, possibly for up to 6 months.

Usual Adult Dose for Pneumonia:

2 g IV or IM every 4 hours. Therapy should continue for 7 to 10 days if pneumococcus pneumonia is suspected and up to 21 days if other organisms are responsible.

Alternatively, 500 mg to 1 g orally every 4 to 6 hours, depending on the nature and severity of the infection.

Usual Adult Dose for Septicemia:

2 g IV or IM every 4 to 6 hours for 14 days, depending on the nature and severity of the infection.

Usual Adult Dose for Sinusitis:

1 to 1.5 g IV or IM or 500 mg to 1 g orally every 4 to 6 hours for 10 to 14 days, depending on the nature and severity of the infection.

Usual Adult Dose for Skin or Soft Tissue Infection:

1 to 1.5 g IV or IM every 4 to 6 hours for 7 days, or for 3 days after acute inflammation resolves, depending on the nature and severity of the infection.

Alternatively, 500 mg orally every 4 to 6 hours may be used for mild infections or follow-up after initial parenteral therapy:

Usual Pediatric Dose for Bacterial Infection:

Neonates:
2000 g: 25 to 50 mg/kg IV or IM every 8 hours.
> 7 days, birthweight > 7 days, birthweight 1200 to 2000 g: 25 to 50 mg/kg IV or IM every 8 hours.
> 7 days, birthweight > 2000 g: 25 to 50 mg/kg IV or IM every 6 hours.

1 month to 12 years:
Mild to moderate infections:
Parenteral: 25 to 37.5 mg/kg IV or IM every 6 hours.
Oral: 12.5 mg/kg every 6 hours.

Severe infections: 150 to 200 mg/kg/day IV or IM in equally divided doses every 4 to 6 hours.

Maximum dose: 12 g/day.


What other drugs will affect oxacillin?


Before taking oxacillin, tell your doctor if you are using any of the following drugs:



  • methotrexate (Rheumatrex, Trexall); or




  • probenecid (Benemid).



This list is not complete and there may be other drugs that can interact with oxacillin. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.



More oxacillin resources


  • Oxacillin Side Effects (in more detail)
  • Oxacillin Dosage
  • Oxacillin Use in Pregnancy & Breastfeeding
  • Drug Images
  • Oxacillin Drug Interactions
  • Oxacillin Support Group
  • 0 Reviews for Oxacillin - Add your own review/rating


  • Oxacillin MedFacts Consumer Leaflet (Wolters Kluwer)

  • Bactocill Monograph (AHFS DI)

  • Bactocill Advanced Consumer (Micromedex) - Includes Dosage Information



Compare oxacillin with other medications


  • Bacterial Infection
  • Bone infection
  • Endocarditis
  • Joint Infection
  • Meningitis
  • Pneumonia
  • Septicemia
  • Sinusitis
  • Skin Infection


Where can I get more information?


  • Your pharmacist can provide more information about oxacillin.

See also: oxacillin side effects (in more detail)


Thursday, 10 December 2009

Colchimax




Colchimax may be available in the countries listed below.


Ingredient matches for Colchimax



Colchicine

Colchicine is reported as an ingredient of Colchimax in the following countries:


  • Spain

Dicycloverine

Dicycloverine hydrochloride (a derivative of Dicycloverine) is reported as an ingredient of Colchimax in the following countries:


  • Spain

International Drug Name Search

Monday, 30 November 2009

Bisoprolol HCT Synthon




Bisoprolol HCT Synthon may be available in the countries listed below.


Ingredient matches for Bisoprolol HCT Synthon



Bisoprolol

Bisoprolol fumarate (a derivative of Bisoprolol) is reported as an ingredient of Bisoprolol HCT Synthon in the following countries:


  • Germany

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Bisoprolol HCT Synthon in the following countries:


  • Germany

International Drug Name Search

Tuesday, 24 November 2009

Loraday




Loraday may be available in the countries listed below.


Ingredient matches for Loraday



Loratadine

Loratadine is reported as an ingredient of Loraday in the following countries:


  • Oman

International Drug Name Search

Tuesday, 27 October 2009

Roxithromycin Sandoz




Roxithromycin Sandoz may be available in the countries listed below.


Ingredient matches for Roxithromycin Sandoz



Roxithromycin

Roxithromycin is reported as an ingredient of Roxithromycin Sandoz in the following countries:


  • Austria

  • Finland

  • Germany

International Drug Name Search

Saturday, 24 October 2009

Simvafar




Simvafar may be available in the countries listed below.


Ingredient matches for Simvafar



Simvastatin

Simvastatin is reported as an ingredient of Simvafar in the following countries:


  • Vietnam

International Drug Name Search

Friday, 23 October 2009

Alprazolam Pazolam




Alprazolam Pazolam may be available in the countries listed below.


Ingredient matches for Alprazolam Pazolam



Alprazolam

Alprazolam is reported as an ingredient of Alprazolam Pazolam in the following countries:


  • Portugal

International Drug Name Search

Monday, 19 October 2009

Etamolin




Etamolin may be available in the countries listed below.


Ingredient matches for Etamolin



Calcium Folinate

Calcium Folinate is reported as an ingredient of Etamolin in the following countries:


  • Peru

International Drug Name Search

Reparil-Gel N




Reparil-Gel N may be available in the countries listed below.


Ingredient matches for Reparil-Gel N



Diethylamine Salicylate

Diethylamine Salicylate is reported as an ingredient of Reparil-Gel N in the following countries:


  • Belgium

  • China

  • Germany

  • Singapore

  • South Africa

Escin

Escin is reported as an ingredient of Reparil-Gel N in the following countries:


  • Belgium

  • China

  • Germany

  • Singapore

  • South Africa

International Drug Name Search

Tuesday, 6 October 2009

Gastrazol




Gastrazol may be available in the countries listed below.


Ingredient matches for Gastrazol



Lansoprazole

Lansoprazole is reported as an ingredient of Gastrazol in the following countries:


  • Venezuela

International Drug Name Search

Friday, 2 October 2009

Betoptic


See also: Generic Betoptic S


Betoptic is a brand name of betaxolol ophthalmic, approved by the FDA in the following formulation(s):


BETOPTIC (betaxolol hydrochloride - solution/drops; ophthalmic)



  • Manufacturer: ALCON

    Approval date: August 30, 1985

    Strength(s): EQ 0.5% BASE [RLD][AT]

Has a generic version of Betoptic been approved?


Yes. The following products are equivalent to Betoptic:


betaxolol hydrochloride solution/drops; ophthalmic



  • Manufacturer: AKORN

    Approval date: June 30, 2000

    Strength(s): EQ 0.5% BASE [AT]


  • Manufacturer: BAUSCH AND LOMB

    Approval date: April 12, 2001

    Strength(s): EQ 0.5% BASE [AT]


  • Manufacturer: NOVEX

    Approval date: September 28, 2000

    Strength(s): EQ 0.5% BASE [AT]


  • Manufacturer: WOCKHARDT

    Approval date: November 16, 2009

    Strength(s): EQ 0.5% BASE [AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Betoptic. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Betoptic.

See also...

  • Betaxolol Drops Consumer Information (Wolters Kluwer)
  • Betaxolol ophthalmic Consumer Information (Cerner Multum)
  • Betaxolol Ophthalmic Advanced Consumer Information (Micromedex)
  • Betaxolol Hydrochloride eent AHFS DI Monographs (ASHP)

Decavac


Pronunciation: TET-a-nus/dif-THEER-ee-a
Generic Name: Tetanus and Diphtheria Toxoids (Td) Vaccine
Brand Name: Decavac


Decavac is used for:

Preventing tetanus and diphtheria infections.


Decavac is a vaccine. It works by stimulating the body to produce antibodies against tetanus and diphtheria.


Do NOT use Decavac if:


  • you allergic to any ingredient in Decavac

  • you have had a severe allergic reaction (eg, severe rash, hives, difficulty breathing, dizziness) to any previous dose of this or a similar vaccine

Contact your doctor or health care provider right away if any of these apply to you.



Before using Decavac:


Some medical conditions may interact with Decavac. Tell your doctor or pharmacist if the patient has any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have a fever, infection, or other recent illness; cancer; a history of Guillain-Barre syndrome or poor health; or a weakened immune system (eg, HIV infection, AIDS)

  • if you have a history of bleeding problems (eg, hemophilia), blood problems (eg, leukemia, lymphoma), or easy bruising or bleeding

  • if you are undergoing chemotherapy or radiation therapy

  • if you have recently received another vaccine

Tell your health care provider if the patient is taking any other medicines, especially any of the following:


  • Anticoagulants (eg, warfarin) because the risk of bleeding at the injection site may be increased

  • Corticosteroids (eg, prednisone), immunosuppressants (eg, cyclosporine), medicines to treat cancer, or other medicines that may weaken the immune system because they may decrease Decavac's effectiveness

This may not be a complete list of all interactions that may occur. Ask your health care provider if Decavac may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Decavac:


Use Decavac as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Decavac is given as an injection at your doctor's office, hospital, or clinic.

  • If you miss a dose of Decavac, contact your doctor as soon as possible to reschedule your dose.

Ask your health care provider any questions you may have about how to use Decavac.



Important safety information:


  • Decavac may cause dizziness. This effect may be worse if you take it with alcohol or certain medicines. Use Decavac with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Tell your doctor or dentist that you take Decavac before you receive any medical or dental care, emergency care, or surgery.

  • Tell your doctor if you will be receiving other vaccines.

  • Decavac may not protect everyone who receives it from tetanus or diphtheria. Discuss any questions or concerns with your doctor.

  • Decavac is not approved for CHILDREN younger than 7 years old; safety and effectiveness in these children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Decavac while you are pregnant. It is not known if Decavac is found in breast milk. If you are or will be breast-feeding while you use Decavac, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Decavac:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Headache; mild fever; minor pain, swelling, or redness at the injection site; tiredness.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blistering or sores at the injection site; fainting; muscle spasms; numbness or tingling of the arms or legs; seizure; severe or persistent dizziness, fever, or vomiting; severe or persistent joint pain; severe or persistent muscle weakness.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Decavac side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.


Proper storage of Decavac:

Decavac is usually handled and stored by a health care provider. If you are using Decavac at home, store Decavac as directed by your pharmacist or health care provider. Protect from light. Keep Decavac out of the reach of children and away from pets.


General information:


  • If you have any questions about Decavac, please talk with your doctor, pharmacist, or other health care provider.

  • Decavac is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Decavac. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Decavac resources


  • Decavac Side Effects (in more detail)
  • Decavac Use in Pregnancy & Breastfeeding
  • Decavac Drug Interactions
  • 0 Reviews for Decavac - Add your own review/rating


Compare Decavac with other medications


  • Diphtheria Prophylaxis
  • Tetanus Prophylaxis

Saturday, 12 September 2009

Gelnique


Gelnique is a brand name of oxybutynin, approved by the FDA in the following formulation(s):


GELNIQUE (oxybutynin chloride - gel; transdermal)



  • Manufacturer: WATSON LABS

    Approval date: January 27, 2009

    Strength(s): 10%(100MG/PACKET) [RLD]

Has a generic version of Gelnique been approved?


No. There is currently no therapeutically equivalent version of Gelnique available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Gelnique. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Compositions and methods for transdermal oxybutynin therapy
    Patent 7,029,694
    Issued: April 18, 2006
    Inventor(s): Ebert; Charles D. & Sanders; Steven W.
    Assignee(s): Watson Laboratories, Inc.
    The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.
    Patent expiration dates:

    • April 26, 2020
      ✓ 
      Patent use: TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
      ✓ 
      Drug product




  • Compositions and methods for transdermal oxybutynin therapy
    Patent 7,179,483
    Issued: February 20, 2007
    Inventor(s): Ebert; Charles D. & Sanders; Steven W.
    Assignee(s): Watson Pharmaceuticals, Inc.
    The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.
    Patent expiration dates:

    • April 26, 2020
      ✓ 
      Patent use: TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • January 27, 2012 - NEW DOSAGE FORM

See also...

  • Gelnique Consumer Information (Drugs.com)
  • Gelnique Gel Consumer Information (Wolters Kluwer)
  • Gelnique topical Consumer Information (Cerner Multum)
  • Gelnique Advanced Consumer Information (Micromedex)
  • Oxybutynin Consumer Information (Drugs.com)
  • Oxybutynin Consumer Information (Wolters Kluwer)
  • Oxybutynin Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Oxybutynin Gel Consumer Information (Wolters Kluwer)
  • Oxybutynin Syrup Consumer Information (Wolters Kluwer)
  • Oxybutynin System Consumer Information (Wolters Kluwer)
  • Oxybutynin Consumer Information (Cerner Multum)
  • Oxybutynin topical Consumer Information (Cerner Multum)
  • Oxybutynin transdermal Consumer Information (Cerner Multum)
  • Oxybutynin Advanced Consumer Information (Micromedex)
  • Oxybutynin Transdermal Advanced Consumer Information (Micromedex)
  • Oxybutynin Chloride AHFS DI Monographs (ASHP)

Friday, 28 August 2009

Prolosan




Prolosan may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Prolosan



Gonadotrophin, Serum

Gonadotrophin, Serum is reported as an ingredient of Prolosan in the following countries:


  • Germany

International Drug Name Search

Monday, 24 August 2009

Viskeen




Viskeen may be available in the countries listed below.


Ingredient matches for Viskeen



Pindolol

Pindolol is reported as an ingredient of Viskeen in the following countries:


  • Netherlands

International Drug Name Search

Friday, 21 August 2009

Fluoxetina Ciclum




Fluoxetina Ciclum may be available in the countries listed below.


Ingredient matches for Fluoxetina Ciclum



Fluoxetine

Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Fluoxetina Ciclum in the following countries:


  • Portugal

International Drug Name Search

Wednesday, 19 August 2009

Xeldrin




Xeldrin may be available in the countries listed below.


Ingredient matches for Xeldrin



Omeprazole

Omeprazole is reported as an ingredient of Xeldrin in the following countries:


  • Bangladesh

International Drug Name Search

Tuesday, 18 August 2009

Quinabic




Quinabic may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Quinabic



Norfloxacin

Norfloxacin nicotinate (a derivative of Norfloxacin) is reported as an ingredient of Quinabic in the following countries:


  • South Africa

International Drug Name Search

Monday, 3 August 2009

Taven




Taven may be available in the countries listed below.


Ingredient matches for Taven



Atorvastatin

Atorvastatin calcium (a derivative of Atorvastatin) is reported as an ingredient of Taven in the following countries:


  • Bangladesh

International Drug Name Search

Friday, 31 July 2009

Simvastatin-Isis




Simvastatin-Isis may be available in the countries listed below.


Ingredient matches for Simvastatin-Isis



Simvastatin

Simvastatin is reported as an ingredient of Simvastatin-Isis in the following countries:


  • Germany

International Drug Name Search

Thursday, 23 July 2009

Destirol




Destirol may be available in the countries listed below.


Ingredient matches for Destirol



Dextropropoxyphene

Dextropropoxyphene hydrochloride (a derivative of Dextropropoxyphene) is reported as an ingredient of Destirol in the following countries:


  • Vietnam

Paracetamol

Paracetamol is reported as an ingredient of Destirol in the following countries:


  • Vietnam

International Drug Name Search

Wednesday, 22 July 2009

Gastifam




Gastifam may be available in the countries listed below.


Ingredient matches for Gastifam



Famotidine

Famotidine is reported as an ingredient of Gastifam in the following countries:


  • Turkey

International Drug Name Search

Tuesday, 21 July 2009

Broomhexine HCl ratiopharm




Broomhexine HCl ratiopharm may be available in the countries listed below.


Ingredient matches for Broomhexine HCl ratiopharm



Bromhexine

Bromhexine hydrochloride (a derivative of Bromhexine) is reported as an ingredient of Broomhexine HCl ratiopharm in the following countries:


  • Netherlands

International Drug Name Search

Saturday, 18 July 2009

Fortal




Fortal may be available in the countries listed below.


Ingredient matches for Fortal



Pentamidine

Pentamidine is reported as an ingredient of Fortal in the following countries:


  • Greece

Pentazocine

Pentazocine is reported as an ingredient of Fortal in the following countries:


  • Belgium

  • Luxembourg

Pentazocine hydrochloride (a derivative of Pentazocine) is reported as an ingredient of Fortal in the following countries:


  • Belgium

International Drug Name Search

Friday, 17 July 2009

Fentadolon




Fentadolon may be available in the countries listed below.


Ingredient matches for Fentadolon



Fentanyl

Fentanyl is reported as an ingredient of Fentadolon in the following countries:


  • Germany

International Drug Name Search

Tuesday, 7 July 2009

Cefazolina Genfar




Cefazolina Genfar may be available in the countries listed below.


Ingredient matches for Cefazolina Genfar



Cefazolin

Cefazolin sodium salt (a derivative of Cefazolin) is reported as an ingredient of Cefazolina Genfar in the following countries:


  • Colombia

International Drug Name Search

Friday, 3 July 2009

Dikoven




Dikoven may be available in the countries listed below.


Ingredient matches for Dikoven



Ketoconazole

Ketoconazole is reported as an ingredient of Dikoven in the following countries:


  • Dominican Republic

International Drug Name Search

Wednesday, 1 July 2009

Tinzaparine sodique




Tinzaparine sodique may be available in the countries listed below.


Ingredient matches for Tinzaparine sodique



Tinzaparin

Tinzaparine sodique (DCF) is known as Tinzaparin in the US.

International Drug Name Search

Glossary

DCFDénomination Commune Française

Click for further information on drug naming conventions and International Nonproprietary Names.

Thursday, 18 June 2009

AFT Leflunomide




AFT Leflunomide may be available in the countries listed below.


Ingredient matches for AFT Leflunomide



Leflunomide

Leflunomide is reported as an ingredient of AFT Leflunomide in the following countries:


  • New Zealand

International Drug Name Search

Friday, 12 June 2009

Nimodipino GES




Nimodipino GES may be available in the countries listed below.


Ingredient matches for Nimodipino GES



Nimodipine

Nimodipine is reported as an ingredient of Nimodipino GES in the following countries:


  • Spain

International Drug Name Search

Dimesul




Dimesul may be available in the countries listed below.


Ingredient matches for Dimesul



Nimesulide

Nimesulide is reported as an ingredient of Dimesul in the following countries:


  • Italy

International Drug Name Search

Thursday, 11 June 2009

EMU-V




EMU-V may be available in the countries listed below.


Ingredient matches for EMU-V



Erythromycin

Erythromycin is reported as an ingredient of EMU-V in the following countries:


  • Ethiopia

International Drug Name Search

Tuesday, 26 May 2009

Flucacid




Flucacid may be available in the countries listed below.


Ingredient matches for Flucacid



Flucloxacillin

Flucloxacillin sodium salt (a derivative of Flucloxacillin) is reported as an ingredient of Flucacid in the following countries:


  • Italy

International Drug Name Search

Friday, 22 May 2009

Citidoline




Citidoline may be available in the countries listed below.


Ingredient matches for Citidoline



Citicoline

Citidoline (DCF) is known as Citicoline in the US.

International Drug Name Search

Glossary

DCFDénomination Commune Française

Click for further information on drug naming conventions and International Nonproprietary Names.

Wednesday, 20 May 2009

Colevastina Lch




Colevastina Lch may be available in the countries listed below.


Ingredient matches for Colevastina Lch



Lovastatin

Lovastatin is reported as an ingredient of Colevastina Lch in the following countries:


  • Peru

International Drug Name Search

Friday, 15 May 2009

Acido Alendronico Arrowblue




Acido Alendronico Arrowblue may be available in the countries listed below.


Ingredient matches for Acido Alendronico Arrowblue



Alendronic Acid

Alendronic Acid is reported as an ingredient of Acido Alendronico Arrowblue in the following countries:


  • Portugal

International Drug Name Search

Wednesday, 13 May 2009

Glucurolactone Lisheng Pharm




Glucurolactone Lisheng Pharm may be available in the countries listed below.


Ingredient matches for Glucurolactone Lisheng Pharm



Glucurolactone

Glucurolactone is reported as an ingredient of Glucurolactone Lisheng Pharm in the following countries:


  • China

International Drug Name Search

Friday, 8 May 2009

Dexmedetomidine Hydrochloride




Dexmedetomidine Hydrochloride may be available in the countries listed below.


Ingredient matches for Dexmedetomidine Hydrochloride



Dexmedetomidine

Dexmedetomidine Hydrochloride (USAN) is known as Dexmedetomidine in the US.

International Drug Name Search

Glossary

USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Tuesday, 5 May 2009

Artix




Artix may be available in the countries listed below.


Ingredient matches for Artix



Celecoxib

Celecoxib is reported as an ingredient of Artix in the following countries:


  • Peru

International Drug Name Search

Wednesday, 15 April 2009

Trip




Trip may be available in the countries listed below.


Ingredient matches for Trip



Amitriptyline

Amitriptyline hydrochloride (a derivative of Amitriptyline) is reported as an ingredient of Trip in the following countries:


  • Bangladesh

International Drug Name Search

Monday, 6 April 2009

Diatex


Pronunciation: VYE-ta-min/BYE-oh-tin/FOE-lik AS-id
Generic Name: Vitamin B Complex/Vitamin C/Biotin/Folic Acid
Brand Name: Examples include: Folbee Plus and Nephrocaps


Diatex is used for:

A dietary supplement for certain patients with high blood levels of homocysteine or kidney failure, or those who are on dialysis or do not receive the proper amount of vitamins from their diet. It may also be used for other conditions as determined by your doctor.


Diatex is a vitamin and folic acid combination. It works by providing vitamins and folic acid to the body to help meet nutritional requirements.


Do NOT use Diatex if:


  • you are allergic to any ingredient in Diatex

Contact your doctor or health care provider right away if any of these apply to you.



Before using Diatex:


Some medical conditions may interact with Diatex. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have anemia (eg, pernicious anemia)

  • if you are receiving dialysis

Some MEDICINES MAY INTERACT with Diatex. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Hydantoins (eg, phenytoin) or levodopa because their effectiveness may be decreased by Diatex

This may not be a complete list of all interactions that may occur. Ask your health care provider if Diatex may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Diatex:


Use Diatex as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Diatex may be taken with or without food. If stomach upset occurs, take with food to reduce stomach irritation.

  • If you miss a dose of Diatex, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Diatex.



Important safety information:


  • Diatex may cause drowsiness. This effect may be worse if you take it with alcohol or certain medicines. Use Diatex with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Do not take large doses of vitamins (megadoses or megavitamin therapy) while you use Diatex unless your doctor tells you to.

  • Diatex contains pyridoxine (vitamin B6) and folic acid. Before you start any new medicine, check the label to see if it has pyridoxine or folic acid in it too. If it does or if you are not sure, check with your doctor or pharmacist.

  • Diatex may interfere with certain lab tests. Be sure your doctor and lab personnel know you are taking Diatex.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Diatex while you are pregnant. It is not known if Diatex is found in breast milk. If you are or will be breast-feeding while you use Diatex, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Diatex:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Drowsiness; headache; mild diarrhea; nausea.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); feeling of swelling of the entire body; numbness or tingling of the skin.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Diatex side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.


Proper storage of Diatex:

Store Diatex at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Diatex out of the reach of children and away from pets.


General information:


  • If you have any questions about Diatex, please talk with your doctor, pharmacist, or other health care provider.

  • Diatex is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Diatex. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Diatex resources


  • Diatex Side Effects (in more detail)
  • Diatex Use in Pregnancy & Breastfeeding
  • Diatex Drug Interactions
  • Diatex Support Group
  • 0 Reviews for Diatex - Add your own review/rating


Compare Diatex with other medications


  • Dietary Supplementation

Brimonidine AFT




Brimonidine AFT may be available in the countries listed below.


Ingredient matches for Brimonidine AFT



Brimonidine

Brimonidine tartrate (a derivative of Brimonidine) is reported as an ingredient of Brimonidine AFT in the following countries:


  • New Zealand

International Drug Name Search

Friday, 3 April 2009

Enalapril M




Enalapril M may be available in the countries listed below.


Ingredient matches for Enalapril M



Enalapril

Enalapril maleate (a derivative of Enalapril) is reported as an ingredient of Enalapril M in the following countries:


  • Japan

International Drug Name Search

Friday, 27 March 2009

Hepsera




In the US, Hepsera (adefovir systemic) is a member of the drug class nucleoside reverse transcriptase inhibitors (NRTIs) and is used to treat Hepatitis B.

US matches:

  • Hepsera

UK matches:

  • Hepsera 10 mg tablets (SPC)

Ingredient matches for Hepsera



Adefovir

Adefovir dipivoxil (a derivative of Adefovir) is reported as an ingredient of Hepsera in the following countries:


  • Argentina

  • Australia

  • Austria

  • Belgium

  • Brazil

  • Canada

  • Chile

  • China

  • Colombia

  • Costa Rica

  • Cyprus

  • Czech Republic

  • Denmark

  • Dominican Republic

  • El Salvador

  • Finland

  • France

  • Germany

  • Greece

  • Guatemala

  • Honduras

  • Hong Kong

  • Hungary

  • Iceland

  • Indonesia

  • Ireland

  • Israel

  • Italy

  • Japan

  • Luxembourg

  • Malaysia

  • Mexico

  • Netherlands

  • New Zealand

  • Nicaragua

  • Norway

  • Panama

  • Peru

  • Philippines

  • Poland

  • Singapore

  • Slovakia

  • Slovenia

  • Spain

  • Sweden

  • Switzerland

  • Taiwan

  • Thailand

  • Turkey

  • United Kingdom

  • United States

  • Venezuela

  • Vietnam

International Drug Name Search

Glossary

SPC Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Wednesday, 25 March 2009

Pressural




Pressural may be available in the countries listed below.


Ingredient matches for Pressural



Indapamide

Indapamide hemihydrate (a derivative of Indapamide) is reported as an ingredient of Pressural in the following countries:


  • Italy

International Drug Name Search

Wednesday, 18 March 2009

Kurgan




Kurgan may be available in the countries listed below.


Ingredient matches for Kurgan



Cefazolin

Cefazolin sodium salt (a derivative of Cefazolin) is reported as an ingredient of Kurgan in the following countries:


  • Spain

International Drug Name Search

Monday, 16 March 2009

Ventolin Inhalador




Ventolin Inhalador may be available in the countries listed below.


Ingredient matches for Ventolin Inhalador



Salbutamol

Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Ventolin Inhalador in the following countries:


  • Spain

International Drug Name Search

Tuesday, 10 March 2009

Combivent Respimat


See also: Generic Combivent


Combivent Respimat is a brand name of albuterol/ipratropium, approved by the FDA in the following formulation(s):


COMBIVENT RESPIMAT (albuterol sulfate; ipratropium bromide - spray, metered; inhalation)



  • Manufacturer: BOEHRINGER INGELHEIM

    Approval date: October 7, 2011

    Strength(s): EQ 0.1MG BASE/INH;0.02MG/INH [RLD]

Has a generic version of Combivent Respimat been approved?


No. There is currently no therapeutically equivalent version of Combivent Respimat available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Combivent Respimat. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Nozzle assembly for preventing back-flow
    Patent 5,405,084
    Issued: April 11, 1995
    Inventor(s): Weston; Terence E. & Dunne; Stephen T.
    Assignee(s): DMW (Technology) Limited
    A nozzle assembly which comprises a nozzle aperture for discharge of a fluid as a spray of droplets, and a conduit in fluid flow communication with the nozzle aperture. The flow of fluid through the conduit is restricted by the minimum effective cross-sectional area of the conduit transverse to the line of flow of fluid through the conduit so that back flow of fluid from the nozzle aperture through the conduit at ambient and operational pressure differentials is substantially prevented. The invention further provides for a method of discharging a fluid as a spray of droplets, and a spray generating device which includes the nozzle assembly of the present invention.
    Patent expiration dates:

    • April 11, 2012
      ✓ 
      Drug product




  • Atomising nozzle and filter and spray generation device
    Patent 5,472,143
    Issued: December 5, 1995
    Inventor(s): Bartels; Frank & Bachtler; Wulf & Dunne; Stephen T. & Eicher; Joachim & Freund; Bernhard & Hart; William B. & Lessmoellmann; Christoph
    Assignee(s): Boehringer Ingelheim International GmbH
    DMW (Technology) Ltd.
    A nozzle assembly for use in atomizing and generating sprays from a fluid. The nozzle assembly includes two members joined together. In one of the two members are formed one or more nozzle outlets, one or more fluid inlets, and a plurality of channels that form filter passageways. The nozzle outlets discharge fluid jets that impinge on one another to thereby atomize the fluid. Alternatively, an impact element or a vortex-generating structure can be used in the nozzle outlet to atomize the fluid.
    Patent expiration dates:

    • September 29, 2013
      ✓ 
      Drug product




  • Atomising devices and methods
    Patent 5,497,944
    Issued: March 12, 1996
    Inventor(s): Weston; Terence E. & Dunne; Stephen T.
    Assignee(s): DMW (Technology) Limited
    A metered dose inhaler for dispensing a fluid medicament as droplets of small mean particle size without the use of pressurized gas or liquefied propellants. A liquid drug is contained in a fluid reservoir, and metered quantities of the drug are successively presented into a reduced cross-section pressure chamber, with non-return valves controlling the flow of liquid through the device. The metered quantity of the drug is then subjected to a sudden and great increase in pressure by releasing a piston into the pressure chamber. The liquid drug is thereby ejected through an atomizing head, to reduce it to a fine atomized spray of small mean particle size, preferably less than approximately 12 micrometers.
    Patent expiration dates:

    • March 12, 2013
      ✓ 
      Drug product




  • Atomizing devices and methods
    Patent 5,662,271
    Issued: September 2, 1997
    Inventor(s): Weston; Terence Edward & Dunne; Stephen Terence
    Assignee(s): Boehringer Ingelheim International GmbH
    A metered dose inhaler comprises a piston which is mounted in a cavity within a body, and is urged by a pre-loaded spring into a reduced cross-section pressure chamber. The piston may be loaded by means of an actuating rod having a handle, and may be latched in a loaded position by a latching means. A liquid drug (e.g. in aqueous solution) is contained in a collapsible bag. Metered quantities of the drug are successively presented in the pressure chamber, and then subjected to a sudden and great increase in pressure, to eject the liquid drug through an atomising head, to reduce it to fine atomised spray of small mean particle size--for example less than 30 micrometers. Non-return valves control the flow of liquid through the device. The sudden pressure pulse is caused be releasing the spring loaded piston, upon depressing an actuating button connected by the latching means.
    Patent expiration dates:

    • September 2, 2014
      ✓ 
      Drug product




  • Atomizing nozzle and filter and spray generating device
    Patent 5,911,851
    Issued: June 15, 1999
    Inventor(s): Bartels; Frank & Bachtler; Wulf & Dunne; Stephen Terence & Eicher; Joachim & Freund; Bernhard & Hart; William Barrie & Lessmoellmann; Christoph
    Assignee(s): Boehringer Ingelheim International GmbH
    A nozzle assembly for use in atomizing and generating sprays from a fluid. The nozzle assembly includes two members joined together. In one of the two members are formed one or more nozzle outlets, one or more fluid inlets, and a plurality of channels that form filter passageways. The nozzle outlets discharge fluid jets that impinge on one another to thereby atomize the fluid. Alternatively, an impact element or a vortex-generating structure can be used in the nozzle outlet to atomize the fluid. Methods are also provided for producing the nozzle assembly by forming the inlets, outlets, and/or channels through electrical or chemical etching or other processes that selectively remove material from at least one face of a nozzle assembly member.
    Patent expiration dates:

    • September 29, 2013
      ✓ 
      Drug product




  • Device for producing high pressure in a fluid in miniature
    Patent 5,964,416
    Issued: October 12, 1999
    Inventor(s): Jaeger; Joachim & Cirillo; Pasquale & Eicher; Joachim & Geser; Johannes
    Assignee(s): Boehringer Ingelheim GmbH
    A miniaturized device for pressurizing fluid. The device includes a hollow piston that provides a fluid path and a valve member. The valve member is configured for axial movement so that the valve axis remains parallel to the piston axis. The valve member is arranged at one end of the hollow piston. The valve member may be partially or completely disposed within the hollow piston. The device is particularly adapted for use in a mechanically operated atomizer to produce an inhalable aerosol of a liquid medicament without the use of propellant gas.
    Patent expiration dates:

    • October 4, 2016
      ✓ 
      Drug product




  • Atomizing nozzle and filter and spray generating device
    Patent 6,007,676
    Issued: December 28, 1999
    Inventor(s): Bartels; Frank & Bachtler; Wulf & Dunne; Stephen Terance & Eicher; Joachim & Freund; Bernhard & Hart; William Barrie & Lessmoellmann; Christoph
    Assignee(s): Boehringer Ingelheim International GmbH
    A nozzle assembly for use in atomizing and generating sprays from a fluid. The nozzle assembly includes two members, each with generally planar surfaces, that are joined together. A first set of channels is formed in the generally planar surface of a first one of the members to form, in cooperation with the generally planar surface of the second of the members, a plurality of filter passageways. A plenum chamber is formed in the first member. The plenum chamber is in fluid communication with and downstream of the plurality of filter passageways. A second set of channels is formed in the generally planar surface of the first member to form, in cooperation with the generally planar surface of the second member, a plurality of nozzle outlet passageways. These nozzle outlet passageways are in fluid communication with the plenum chamber. The nozzle outlet passageways include a plurality of nozzle outlets which are adapted to discharge a plurality of fluid jets that impinge on one another to thereby atomize a flow of fluid.
    Patent expiration dates:

    • September 29, 2013
      ✓ 
      Drug product




  • Mechanical counter for a metering apparatus
    Patent 6,149,054
    Issued: November 21, 2000
    Inventor(s): Cirrillo; Pasquale & Eicher; Joachim & Fiol; Andreas
    Assignee(s): Boehringer Ingelheim International GmbH
    A metering apparatus for metering for example a medicament requires a device with which the number of metering portions is displayed. The known display devices however are not suitable for a metering apparatus having two housing portions which are rotatable relative to each other. The mechanical counter for a metering apparatus of that kind comprises at least one spindle with rotary locking, whose axis extends in parallel relationship with the axis of the metering apparatus and which is disposed in the region of a peripheral surface of the apparatus. The spindle is automatically driven by way of a transmission assembly when the metering apparatus is actuated. The number of metering portions already discharged and the number of petering portions permitted in total is quasi-continuously displayed by the mechanical counter. The transmission ration of the transmission assembly can be designed to cover a wide range. The cursor serving for display purposes can be reset on the spindle. The permissible period of use of a metering apparatus which can be used for a plurality of supply containers can be reliably viewed.
    Patent expiration dates:

    • December 19, 2016
      ✓ 
      Drug product




  • Device for mounting a component exposed to a pressurized fluid
    Patent 6,176,442
    Issued: January 23, 2001
    Inventor(s): Eicher; Joachim & Geser; Johannes
    Assignee(s): Boehringer Ingelheim International GmbH
    The mounting of a component subjected to pressure from a fluid requires special precautions if the component is made of wear resistant, hard and hence generally brittle material and may be destroyed by locally raised stresses. A fluidic component of this kind, made, for example, of silicon/glass is arranged in an elastomeric shaped component, made, for example, of silicon rubber. The inner contours of the elastomeric shaped component correspond to the outer contours of the fluidic component. The outer contours of the shaped component corresponds to the inner contours of a holder. Due to this "floating mounting" there are no unacceptable local pressure peaks and no deformation of the fluidic component. The device is particularly suitable for mounting a fluidic component made of glass or silicon, or miniature dimensions, subject to high pressure.
    Patent expiration dates:

    • October 4, 2016
      ✓ 
      Drug product




  • Locking mechanism for a spring-actuated device
    Patent 6,453,795
    Issued: September 24, 2002
    Inventor(s): Joachim; Eicher & Michael; Schyra & Richard; Forster
    Assignee(s): Boehringer Ingelheim International GmbH
    A spring-actuated output drive device is used for example in medical aerosol therapy for a miniaturised high-pressure producing device for atomising a small dose of a liquid medicament. A locking-stressing-mechanism for such an output d rive device is to be stressed with the application of a relatively small amount of force and is to be released with one hand and is to operate reliably over a prolonged period of time. The locking-stressing-mechanism comprises a force step-up transmission, for example a screw thrust transmission for stressing the spring, an annularly arranged locking member with engaging locking surfaces, two abutments for limiting the travel of the spring and a release button. It is compact, economical to produce, easy to assemble and comprises components with a low rate of wear. It can be reliably and easily handled by unskilled persons, even when high spring forces are involved. A medicament to be atomised can thus be metered with a very high degree of accuracy.
    Patent expiration dates:

    • December 5, 2016
      ✓ 
      Drug product




  • Atomizing nozzle an filter and spray generating device
    Patent 6,503,362
    Issued: January 7, 2003
    Inventor(s): Frank; Bartels & Wulf; Bachtler & Stephen Terence; Dunne & Joachim; Eicher & Bernhard; Freund & William Barrie; Hart & Christoph; Lessmoellmann
    Assignee(s): Boehringer Ingelheim International GmbH
    A nozzle assembly for use in atomizing and generating sprays from a fluid. The nozzle assembly includes two members, each with generally planar surfaces, that are joined together. A first set of channels is formed in the generally planar surface of a first one of the members to form, in cooperation with the generally planar surface of the second of the members, a plurality of filter passageways. A plenum chamber is formed in the first member. The plenum chamber is in fluid communication with and downstream of the plurality of filter passageways. A second set of channels is formed in the generally planar surface of the first member to form, in cooperation with the generally planar surface of the second member, a plurality of nozzle outlet passageways. These nozzle outlet passageways are in fluid communication with the plenum chamber. The nozzle outlet passageways include a plurality of nozzle outlets which are adapted to discharge a plurality of fluid jets that impinge on one another to thereby atomize a flow of fluid.
    Patent expiration dates:

    • September 29, 2013
      ✓ 
      Drug product




  • Device for producing high pressure in a fluid in miniature
    Patent 6,726,124
    Issued: April 27, 2004
    Inventor(s): Joachim; Jaeger & Pasquale; Cirillo & Joachim; Eicher & Johannes; Geser & Bernhard; Freund & Bernd; Zierenberg
    Assignee(s): Boehringer International GmbH
    A miniaturized device for pressurizing fluid. The device includes a hollow piston that provides a fluid path and a valve member. The valve member is configured for axial movement so that the valve axis remains parallel to the piston axis. The valve member is arranged at one end of the hollow piston. The valve member may be partially or completely disposed within the hollow piston. The device is particularly adapted for use in a mechanically operated atomizer to produce an inhalable aerosol of a liquid medicament without the use of propellant gas.
    Patent expiration dates:

    • October 4, 2016
      ✓ 
      Drug product




  • Microstructured filter
    Patent 6,846,413
    Issued: January 25, 2005
    Inventor(s): Kadel; Klaus & Geser; Johannes & Eicher; Joachin & Freund; Bernhard & Dunne; Stephen Terence & Bachtler; Wulf
    Assignee(s): Boehringer Ingelheim International GmbH
    A microstructured filter for a fluid, the filter having an inlet for unfiltered fluid and an outlet for filtered fluid, the filter comprising: a plurality of projections (7) which are arranged in at least two rows (3) in mutually juxtaposed relationship and which project out of a base plate (1) and which are an integral component of the base plate, a plurality of passages (8) between the projections (7), and a cover plate which is securable to the base plate to cover the projections (7) and the passages (8), wherein the passages form a plurality of through paths from the inlet to the outlet, said inlet comprises an elongate inlet slot (5) for the unfiltered fluid, which extends over approximately the entire filter width and which is approximately as high as the projection (7) projecting out of the base plate, on the outlet side of the filter. The filter according to the invention remains operational, even if a part of the filter area is obstructed. The filter is used for example in an atomizer with which an aerosol is produced from a fluid which contains a medicament.
    Patent expiration dates:

    • August 28, 2018
      ✓ 
      Drug product




  • Microstructured filter
    Patent 6,977,042
    Issued: December 20, 2005
    Inventor(s): Kadel; Klaus & Geser; Johannes & Eicher; Joachim & Freund; Bernhard & Dunne; Stephen Terence & Bachtler; Wulf
    A microstructured filter having an inlet for unfiltered fluid; an outlet for filtered fluid; a plurality of projections which are arranged in at least two rows in mutually juxtaposed relationship, project out of a base plate and are an integral component of the base plate; a plurality of passages between the projections and a cover plate which is securable to the base plate to cover the projections and the passages. The passages form a plurality of through paths from the inlet to the outlet. The inlet includes an elongate inlet slot for the unfiltered fluid that extends over approximately the entire filter width and is approximately as high as the projection on the outlet side of the filter.
    Patent expiration dates:

    • August 28, 2018
      ✓ 
      Drug product




  • Cartridge for a liquid
    Patent 6,988,496
    Issued: January 24, 2006
    Inventor(s): Eicher; Joachim & Geser; Johannes & Hausmann; Matthias & Schyra; Michael & Wuttke; Gilbert & Fiol; Andreas & Kladders; Heinrich & Hochrainer; Dieter & Zierenberg; Bernd
    Assignee(s): Boehringer Ingelheim International GmbH
    For meteredly dispensing a liquid over a period of several months from a container which can be stored over a long period of time, the need is for a container which is practically diffusion-tight and in which the liquid does not come into contact with the ambient atmosphere. The cartridge according to the invention is a three-shell container comprising a collapsible bag which contains the liquid, a container which is stable in respect of shape and a stiff metal casing. The cartridge can be releasably connected to a dispensing device. The cartridge can be provided with a micro-opening with which the time for pressure equalisation between the cartridge and the ambient atmosphere can be adjusted. The cartridge is suitable for aqueous and for alcoholic liquids which contain a pharmacologically active substance. The liquid in the cartridge is protected from external influences. The cartridge can be used in an atomiser for producing an inhalable aerosol for the treatment of illnesses.
    Patent expiration dates:

    • February 23, 2020
      ✓ 
      Drug product




  • Device for producing high pressure in a fluid in miniature
    Patent 7,104,470
    Issued: September 12, 2006
    Inventor(s): Jaeger; Joachim & Cirillo; Pasquale & Eicher; Joachim & Geser; Johannes & Freund; Bernhard & Zierenberg; Bernd
    Assignee(s): Boehringer Ingelheim International GmbH
    A miniaturized device for pressurizing fluid. The device includes a hollow piston that provides a fluid path and a valve member. The valve member is configured for axial movement so that the valve axis remains parallel to the piston axis. The valve member is arranged at one end of the hollow piston. The valve member may be partially or completely disposed within the hollow piston. The device is particularly adapted for use in a mechanically operated atomizer to produce an inhalable aerosol of a liquid medicament without the use of propellant gas.
    Patent expiration dates:

    • October 4, 2016
      ✓ 
      Drug product




  • Atomising nozzle and filter and spray generating device
    Patent 7,246,615
    Issued: July 24, 2007
    Inventor(s): Bartels; Frank & Bachtler; Wulf & Dunne; Stephen T & Eicher; Joachim & Freund; Bernhard & Hart; William B & Lessmoellmann; Christoph
    Assignee(s): Boehringer International GmbH
    A nozzle assembly for use in atomizing and generating sprays from a fluid. The nozzle assembly includes two members, each with generally planar surfaces, that are joined together. A first set of channels is formed in the generally planar surface of a first one of the members to form, in cooperation with the generally planar surface of the second of the members, a plurality of filter passageways. A plenum chamber is formed in the first member. The plenum chamber is in fluid communication with and downstream of the plurality of filter passageways. A second set of channels is formed in the generally planar surface of the first member to form, in cooperation with the generally planar surface of the second member, a plurality of nozzle outlet passageways. These nozzle outlet passageways are in fluid communication with the plenum chamber. The nozzle outlet passageways include a plurality of nozzle outlets which are adapted to discharge a plurality of fluid jets that impinge on one another to thereby atomize a flow of fluid.
    Patent expiration dates:

    • May 31, 2016
      ✓ 
      Drug product




  • Piston-pumping system having o-ring seal properties
    Patent 7,284,474
    Issued: October 23, 2007
    Inventor(s): Eigemann; Jutta & Geser; Johannes
    Assignee(s): Boehringer Ingelheim International GmbH
    The present invention relates to a piston pumping system for substantially gas-free measurement and/or pumping of predetermined quantities of liquids, preferably pharmaceutical liquids containing oxidation-prone ingredients. Preferably, the system is used as a micropump or as a component thereof in medical devices such as transdermal therapeutic systems, for example.
    Patent expiration dates:

    • August 26, 2024
      ✓ 
      Drug product




  • Blocking device for a locking stressing mechanism having a spring-actuated output drive device
    Patent 7,396,341
    Issued: July 8, 2008
    Inventor(s): Schyra; Michael & Wachtel; Herbert
    Assignee(s): Boehringer Ingelheim International GmbH
    A locking-stressing-mechanism with spring-actuated output drive and a counter with which an apparatus of this kind is fitted, accommodated in a two part housing the two parts of which are mounted to be rotatable relative to each other, can be blocked by means of a pre-stressed leaf spring. The leaf spring is initially accommodated in a recess in the wall of one housing part. As soon as the permitted number of actuations has been reached a push rod pushes the leaf spring out of its resting position. The leaf spring then jumps into a recess in the wall of the other housing part and the two housing parts can no longer be rotated relative to each other. The push rod may be mounted on the pointer of the counter. This blocking device can only be overcome by the application of a force which is sufficient to destroy the device. The device is suitable for blocking a high pressure atomiser or a needleless injector with which a fluid is atomised to form an aerosol or a fluid is injected into a biological tissue.
    Patent expiration dates:

    • October 10, 2026
      ✓ 
      Drug product




  • Cartridge for a liquid
    Patent 7,802,568
    Issued: September 28, 2010
    Inventor(s): Eicher; Joachim & Geser; Johannes & Hausmann; Matthias & Schyra; Michael & Wuttke; Gilbert & Fiol; Andreas & Kladders; Heinrich & Hochrainer; Dieter & Zierenberg; Bernd
    Assignee(s): Boehringer Ingelheim International GmbH
    For meteredly dispensing a liquid over a period of several months from a container which can be stored over a long period of time, the need is for a container which is practically diffusion-tight and in which the liquid does not come into contact with the ambient atmosphere. The cartridge according to the invention is a three-shell container comprising a collapsible bag which contains the liquid, a container which is stable in respect of shape and a stiff metal casing. The cartridge can be releasably connected to a dispensing device. The cartridge can be provided with a micro-opening with which the time for pressure equalisation between the cartridge and the ambient atmosphere can be adjusted. The cartridge is suitable for aqueous and for alcoholic liquids which contain a pharmaceutically active substance. The liquid in the cartridge is protected from external influences. The cartridge can be used in an atomiser for producing an inhalable aerosol for the treatment of illnesses.
    Patent expiration dates:

    • February 26, 2019
      ✓ 
      Drug product




  • Device for clamping a fluidic component
    Patent 7,837,235
    Issued: November 23, 2010
    Inventor(s): Geser; Johannes & Hausmann; Matthias
    Assignee(s): Boehringer Ingelheim International GmbH
    A fluidic component is arranged in an elastomeric shaped part, the contour of which is matched to the outer contour of the component and to the inner contour of a holder. The elastomeric shaped part is chamfered towards the fluidic component on its pressure side. When the holder is assembled, the elastomeric shaped part is deformed by a projection provided on a mating part and is put under uniformly distributed internal tension, after which the elastomeric shaped part surrounds the fluidic component to its full height.
    Patent expiration dates:

    • March 13, 2028
      ✓ 
      Drug product




  • Microstructured high pressure nozzle with built-in filter function
    Patent 7,896,264
    Issued: March 1, 2011
    Inventor(s): Eicher; Joachim & Geser; Johannes & Hausmann; Matthias & Reinecke; Holger
    Assignee(s): Boehringer Ingelheim International GmbH
    A microstructured nozzle consists of a number of channels produced by microstructuring a plate-shaped member. In the nozzle the channels are located between projections which are arranged side by side in rows and project from a base plate. This microstructured base plate is covered with a cover plate. The channels are narrowly defined in terms of shape, cross sectional area and length. The nozzle contains a filter as the primary structure and a secondary structure downstream of the filter. The nozzle is used, for example, with an atomiser which produces an aerosol from a fluid containing a medicament.
    Patent expiration dates:

    • May 26, 2025
      ✓ 
      Drug product




  • Container provided with a pressure equalization opening
    Patent 7,988,001
    Issued: August 2, 2011
    Inventor(s): Kuehn; Torsten & Metzger; Burkhard Peter
    Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG
    A process for producing a container comprising an outer container, an inner bag disposed therein and a pressure equalisation opening disposed in the outer container, and a container produced according to this process, is described, wherein a pre-moulding, comprising two coaxial tubes, is first produced by co-extrusion with the help of a blow mould and with an outwardly-projecting base seam being formed. The process forms a pressure equalisation opening in the outer container without endangering the integrity of the container, wherein a lower wastage rate and higher productivity are achieved. To do this, the base seam is partially cut off and a force which acts in the direction of the seam is introduced into the pre-moulding, which has a temperature of 40 degrees C. to 70 degrees C., which force breaks open and plastically deforms the base seam so that a pressure equalisation opening is formed in the base area.
    Patent expiration dates:

    • August 4, 2021
      ✓ 
      Drug product



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • October 7, 2014 - NEW PRODUCT

See also...

  • Combivent Respimat Advanced Consumer Information (Micromedex)
  • Albuterol/Ipratropium Aerosol Consumer Information (Wolters Kluwer)
  • Albuterol/Ipratropium Solution Consumer Information (Wolters Kluwer)
  • Albuterol and ipratropium inhalation Consumer Information (Cerner Multum)
  • Ratio-Ipra Sal Udv Advanced Consumer Information (Micromedex)
  • Ipratropium and albuterol Inhalation, oral/nebulization Advanced Consumer Information (Micromedex)